Inactivating LATS2 Variation Drives Tumor Progression and Resistance to Anti-PD-1 Therapy in Intrahepatic Cholangiocarcinoma - PubMed
5 hours ago
- #Intrahepatic cholangiocarcinoma
- #LATS2
- #Immunotherapy
- LATS2 variations (mutations and copy number loss) are found in 3% and 34% of intrahepatic cholangiocarcinoma (ICC) cases, respectively.
- LATS2 inactivation leads to decreased protein expression, increased tumor recurrence, and poor overall survival in ICC patients.
- Inactivation of LATS2 suppresses the Hippo signaling pathway, causing YAP activation, which promotes immune evasion and resistance to anti-PD-1 therapy.
- The study suggests LATS2 as a potential biomarker for precision therapy in ICC.